Quality improvement in an anticoagulation clinic: Development of a new treatment protocol

Journal of Nursing Care Quality

Volumn 27, Issue 2, 2012, Pages 161-170

  Carver, Heather R ^a   Studeny, Mark ^a   Gress, Todd W ^b   Wood, Kathryn A ^c,d  

^a Cardiovascular Services   (United States)

^b Department of Internal Medicine ^*  (United States)

^c MARSHALL UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anticoagulants; anticoagulation clinics; evidence based practice; nurse led clinic; quality improvement; warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; FEMALE; HEART VALVE REPLACEMENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; NURSING; NURSING ADMINISTRATION RESEARCH; NURSING EVALUATION RESEARCH; NURSING PRACTICE; ORGANIZATION AND MANAGEMENT; OUTPATIENT DEPARTMENT; PILOT STUDY; STANDARD; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME;

ADULT; AGED; AMBULATORY CARE FACILITIES; ANTICOAGULANTS; CLINICAL PROTOCOLS; EFFICIENCY, ORGANIZATIONAL; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; NURSE'S PRACTICE PATTERNS; NURSING ADMINISTRATION RESEARCH; NURSING EVALUATION RESEARCH; PILOT PROJECTS; QUALITY IMPROVEMENT; TREATMENT OUTCOME; WARFARIN;

EID: 84857915366     PISSN: 10573631     EISSN: None     Source Type: Journal    
DOI: 10.1097/NCQ.0b013e31823e83fd     Document Type: Article

References (18)

1. Garcia DA, Witt DM, Hylek E, et al. Delivery of optimized anticoagulant therapy: Consensus statement from the anticoagulation forum. Ann Pharmacother. 2008;42(7):979-988.
2. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6, suppl): 160S-198S.
3. Nieuwlaat R, Barker L, Kim YK, Eikelboom JW, Yusuf S, Connolly SJ. Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thromb Res. 2010;125(4):e128-e131.
4. Rose AJ, Berlowitz DR, Frayne SM, Hylek EM. Measuring quality of oral anticoagulation care: Extending quality measurement to a new field. Jt Comm J Qual Patient Saf. 2009;35(3):146-155.
5. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics 2010 update. A report from the American Heart Association. Circulation. 2010;121(12):e1-e170.
6. Spyropoulos AC, Turpie AG, Kaatz S, Douketis J, Jacobsen A, Petersen H. Perioperative bridging therapy with unfractionated heparin or low-molecularweight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN registry). Am J Cardiol. 2008;102(7):883-889.
7. Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. Circulation. 2008;118(15):e523-e661.
8. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with lowmolecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving longterm oral anticoagulant therapy. Chest. 2004;125(5): 1642-1650.
9. Rose AJ, Hylek EM, Berlowitz DR, Ash AS, Reisman JI, Ozonoff A. Prompt repeat testing after out-ofrange INR values: A quality indicator for anticoagulation care. Circ Cardiovasc Qual Outcomes. 2011;4(3):276-282.
10. DixonD, Peek B, Reeve R. Safety of enoxaparin bridge therapy in patientswith mechanical heart valves. Ann Pharmacother. 2008;42(1):143-144.
11. O'Neill JL, Flanagan PS, Zaleon CR, Copeland LA. Safety of outpatient dalteparin therapy in veterans with mechanical heart valves. Pharmacother. 2005;25(11):1560-1565.
12. Dentali F, Riva N, Malato A, Saccullo G, Siragusa S, Ageno W. Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. J Thoracic Cardiovasc Surg. 2009;137(1): 91-93.
13. Clark NP, Witt DM, Delate T, et al. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: The low INR study. Pharmacother. 2008;28(8):960-967.
14. Brophy DF, Sica DA. Use of enoxaparin in patients with chronic kidney disease: Safety considerations. Drug Saf. 2007;30(11):991-994.
15. van Leeuwen Y, Rosendaal FR, Cannegieter SC. Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. J Thromb Haemost. 2008;6(3):451-456.
16. Veeger NJ, Piersma-WichersM, Tijssen JG, Hillege HL, van der Meer J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol. 2005;128(4):513-519.
17. Brixey JJ, Robinson DJ, Johnson CW, Johnson TR, Turley JP, Zhang J. A concept analysis of the phenomenon interruption. Adv Nurs Science. 2007;30(1): E26-e42.
18. Laxmisan A, Hakimzada F, Sayan OR, Green RA, Zhang J, Patel VL. Themultitasking clinician: Decisionmaking and cognitive demand during and after team handoffs in emergency care. Int J Med Informatics. 2007;76(11):801-811.